Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized clinically by cognitive decline and memory loss. The pathological features are amyloid-β peptide (Aβ) plaques and intracellular neurofibrillary tangles. Many studies have suggested that oxidative damage induced by reactive oxygen species (ROS) is an important mechanism for AD progression. Our recent study demonstrated that oxidative stress could further impair mitochondrial function. In the present study, we adopted a transgenic mouse model of AD (mAPP, overexpressing AβPP/Aβ in neurons) and performed redox measurements using in vivo electron paramagnetic resonance (EPR) imaging with methoxycarbamyl-proxyl (MCP) as a redox-sensitive probe for studying oxidative stress in an early stage of pathology in a transgenic AD mouse model. Through assessing oxidative stress, mitochondrial function and cognitive behaviors of mAPP mice at the age of 8-9 months, we found that oxidative stress and mitochondrial dysfunction appeared in the early onset of AD. Increased ROS levels were associated with defects of mitochondrial and cognitive dysfunction. Notably, the in vivo EPR method offers a unique way of assessing tissue oxidative stress in living animals under noninvasive conditions, and thus holds a potential for early diagnosis and monitoring the progression of AD.
Van CauwenbergheC, Van BroeckhovenC, SleegersK (2015) The genetic landscape of Alzheimer disease: Clinical implications and perspectives. Genet Med. doi: 10.1038/gim.2015.117
AlikhaniN, GuoL, YanS, DuH, PinhoCM, ChenJX, GlaserE, YanSS (2011) Decreased proteolytic activity of the mitochondrial amyloid-beta degrading enzyme, PreP peptidasome, in Alzheimer’s disease brain mitochondria. J Alzheimers Dis27, 75–87.
5.
DuH, GuoL, FangF, ChenD, SosunovAA, McKhannGM, YanY, WangC, ZhangH, MolkentinJD, Gunn-MooreFJ, VonsattelJP, ArancioO, ChenJX, YanSD (2008) Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nat Med14, 1097–1105.
6.
CasadoA, Encarnacion Lopez-FernandezM, Concepcion CasadoM, de La TorreR (2008) Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem Res33, 450–458.
7.
CristalliDO, ArnalN, MarraFA, de AlanizMJ, MarraCA (2012) Peripheral markers in neurodegenerative patients and their first-degree relatives. J Neurol Sci314, 48–56.
8.
SinclairAJ, BayerAJ, TeamM, JohnstonJ, WarnerC, MaxwellSRJ (1998) Altered plasma antioxidant status in subjects with Alzheimer’s disease and vascular dementia. Int J Geriat Psychiatry13, 840–845.
9.
IharaY, HayabaraT, SasakiK, FujisawaY, KawadaR, YamamotoT, NakashimaY, YoshimuneS, KawaiM, KibataM, KurodaS (1997) Free radicals and superoxide dismutase in blood of patients with Alzheimer’s disease and vascular dementia. J Neurol Sci153, 76–81.
10.
EnnsGM, KinsmanSL, PerlmanSL, SpicerKM, AbdenurJE, CohenBH, AmagataA, BarnesA, KheifetsV, ShraderWD, ThoolenM, BlankenbergF, MillerG (2012) Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab105, 91–102.
11.
DrummondGR, SelemidisS, GriendlingKK, SobeyCG (2011) Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov10, 453–471.
12.
KarunakaranU, ParkKG (2013) A systematic review of oxidative stress and safety of antioxidants in diabetes: Focus on islets and their defense. Diabetes Metab J37, 106–112.
13.
McCartyMF, Barroso-ArandaJ, ContrerasF (2010) Oxidative stress therapy for solid tumors –A proposal. Med Hypotheses74, 1052–1054.
DuH, GuoL, YanS, SosunovAA, McKhannGM, YanSS (2010) Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model. Proc Natl Acad Sci U S A107, 18670–18675.
19.
KuppusamyP, AfeworkiM, ShankarRA, CoffinD, KrishnaMC, HahnSM, MitchellJB, ZweierJL (1998) In vivo electron paramagnetic resonance imaging of tumor heterogeneity and oxygenation in a murine model. Cancer Res58, 1562–1568.
20.
KuppusamyP, LiH, IlangovanG, CardounelAJ, ZweierJL, YamadaK, KrishnaMC, MitchellJB (2002) Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res62, 307–312.
21.
GanX, WuL, HuangS, ZhongC, ShiH, LiG, YuH, Howard SwerdlowR, Xi ChenJ, YanSS (2014) Oxidative stress-mediated activation of extracellular signal-regulated kinase contributes to mild cognitive impairment-related mitochondrial dysfunction. Free Radic Biol Med75, 230–240.
22.
KuppusamyP, ZweierJL (1996) A forward-subtraction procedure for removing hyperfine artifacts in electron paramagnetic resonance imaging. Magn Reson Med35, 316–322.
23.
VorheesCV, WilliamsMT (2006) Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat Protoc1, 848–858.
24.
MuckeL, MasliahE, YuGQ, MalloryM, RockensteinEM, TatsunoG, HuK, KholodenkoD, Johnson-WoodK, McConlogueL (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci20, 4050–4058.
25.
CaspersenC, WangN, YaoJ, SosunovA, ChenX, LustbaderJW, XuHW, SternD, McKhannG, YanSD (2005) Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J19, 2040–2041.
26.
ArancioO, ZhangHP, ChenX, LinC, TrincheseF, PuzzoD, LiuS, HegdeA, YanSF, SternA, LuddyJS, LueLF, WalkerDG, RoherA, ButtiniM, MuckeL, LiW, SchmidtAM, KindyM, HyslopPA, SternDM, Du YanSS (2004) RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J23, 4096–4105.
DuH, GuoL, ZhangW, RydzewskaM, YanS (2011) Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. Neurobiol Aging32, 398–406.
30.
EmotoMC, Sato-AkabaH, HirataH, FujiiHG (2014) Dynamic changes in the distribution and time course of blood-brain barrier-permeative nitroxides in the mouse head with EPR imaging: Visualization of blood flow in a mouse model of ischemia. Free Radic Biol Med74, 222–228.
31.
ArticleJ, ShingoM, IchiroK, ToyoshiI, HajimeN, HideoU (2003) Confirmation of superoxide generation via xanthine oxidase in streptozotocin-induced diabetic mice. Free Radic Res37, 767–772.
32.
PhumalaN, IdeT, UtsumiH (1999) Noninvasive evaluation of in vivo free radical reactions catalyzed by iron using in vivo ESR spectroscopy. Free Radic Biol Med26, 1209–1217.
33.
YamadaKI, KuppusamyP, EnglishS, YooJ, IrieA, SubramanianS, MitchellJB, KrishnaMC (2002) Feasibility and assessment of non-invasive in vivo redox status using electron paramagnetic resonance imaging. Acta Radiol43, 433–440.
HolleyAE, CheesemanKH (1993) Measuring free radical reactions in vivo. Br Med Bull49, 494–505.
42.
KohenR, NyskaA (2002) Oxidation of biological systems: Oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol30, 620–650.
43.
ReddyPH (2008) Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med10, 291–315.
44.
MaurerI, ZierzS, MollerHJ (2000) A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging21, 455–462.
45.
BlassJP (2000) The mitochondrial spiral. An adequate cause of dementia in the Alzheimer’s syndrome. Ann N Y Acad Sci924, 170–183.
46.
SheehanJP, SwerdlowRH, MillerSW, DavisRE, ParksJK, ParkerWD, TuttleJB (1997) Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer’s disease. J Neurosci17, 4612–4622.
ReddyPH, BealMF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol Med14, 45–53.
49.
LeunerK, HauptmannS, Abdel-KaderR, ScherpingI, KeilU, StrosznajderJB, EckertA, MullerWE (2007) Mitochondrial dysfunction: The first domino in brain aging and Alzheimer’s disease?. Antioxid Redox Signal9, 1659–1675.
50.
HauptmannS, ScherpingI, DroseS, BrandtU, SchulzKL, JendrachM, LeunerK, EckertA, MullerWE (2009) Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging30, 1574–1586.
51.
YaoJ, IrwinRW, ZhaoL, NilsenJ, HamiltonRT, BrintonRD (2009) Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A106, 14670–14675.
52.
BlassJP (2003) Cerebrometabolic abnormalities in Alzheimer’s disease. Neurol Res25, 556–566.
53.
SwerdlowRH, KhanSM (2004) A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease. Med Hypotheses63, 8–20.
54.
SwerdlowRH, KhanSM (2009) The Alzheimer’s disease mitochondrial cascade hypothesis: An update. Exp Neurol218, 308–315.
OddoS, CaccamoA, ShepherdJD, MurphyMP, GoldeTE, KayedR, MetherateR, MattsonMP, AkbariY, LaFerlaFM (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron39, 409–421.
58.
HsiaAY, MasliahE, McConlogueL, YuGQ, TatsunoG, HuK, KholodenkoD, MalenkaRC, NicollRA, MuckeL (1999) Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc Natl Acad Sci U S A96, 3228–3233.
59.
LiQX, MaynardC, CappaiR, McLeanCA, ChernyRA, LynchT, CulvenorJG, TrevaskisJ, TannerJE, BaileyKA, CzechC, BushAI, BeyreutherK, MastersCL (1999) Intracellular accumulation of detergent-soluble amyloidogenic A beta fragment of Alzheimer’s disease precursor protein in the hippocampus of aged transgenic mice. J Neurochem72, 2479–2487.
60.
TakahashiRH, MilnerTA, LiF, NamEE, EdgarMA, YamaguchiH, BealMF, XuH, GreengardP, GourasGK (2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol161, 1869–1879.
61.
ReddyPH, McWeeneyS, ParkBS, ManczakM, GutalaRV, PartoviD, JungY, YauV, SearlesR, MoriM, QuinnJ (2004) Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: Up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer’s disease.. Hum Mol Genet13, 1225–1240.
62.
ReddyPH, ManiG, ParkBS, JacquesJ, MurdochG, WhetsellWJr, KayeJ, ManczakM (2005) Differential loss of synaptic proteins in Alzheimer’s disease: Implications for synaptic dysfunction. J Alzheimers Dis7, 103–117; discussion 173–180.
63.
NunomuraA, PerryG, AlievG, HiraiK, TakedaA, BalrajEK, JonesPK, GhanbariH, WatayaT, ShimohamaS, ChibaS, AtwoodCS, PetersenRB, SmithMA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol60, 759–767.
64.
BillingsLM, OddoS, GreenKN, McGaughJL, LaFerlaFM (2005) Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron45, 675–688.
65.
LeissringMA, FarrisW, WuX, ChristodoulouDC, HaigisMC, GuarenteL, SelkoeDJ (2004) Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem J383, 439–446.
66.
SchildgenV, WulfertM, GattermannN (2011) Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes. Exp Hematol39, 666–675e661.
67.
ArthurCR, MortonSL, DunhamLD, KeeneyPM, BennettJPJr (2009) Parkinson’s disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance. Mol Neurodegener4, 37.
